Johnson & Johnson selects lead COVID-19 vaccine candidate and targets September Phase I study
Johnson & Johnson announced that it has selected a candidate for a COVID-19 vaccine from potential constructs it has been investigating since January, and is targeting a Phase 1 study for September.
Paul Stoffels, Chief Scientific Officer at the company, said: “Supported by the global production capability that we are scaling up in parallel to this testing, we expect a vaccine could be ready for emergency use in early 2021.”
Johnson & Johonson has been working with the Beth Israel Deaconess Medical Center, part of Harvard Medical School, on vaccine candidates. It used AdVac technology to investigate what treatment showed the most potential in producing an immune response.
The vaccine they selected will now be manufactured, while two other treatments are on standby. The company said that the same technology that developed their HIV and Ebola vaccine candidates was also used here
To speed up the long process this type of treatment usually takes to trial, Johnson & Johnson have expanded their partnership with the US Biomedical Advanced Research and Development Authority (BARDA). They will both commit $1 billion to research and development, as well as clinical testing, of coronavirus vaccines.
Johnson & Johnson will expand its manufacturing capacity to develop any potential vaccines. It aims to enable rapid production to create one billion doses.
Vaxart has announced topline data from its phase 2 challenge study which assessed its oral …
Valneva and Pfizer have announced positive paediatric and adolescent immunogenicity and safety data for their …